David A. Reis Sells 55,020 Shares of Genesis Healthcare Inc (GEN) Stock

Genesis Healthcare Inc (NYSE:GEN) Director David A. Reis sold 55,020 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $1.67, for a total transaction of $91,883.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David A. Reis also recently made the following trade(s):

  • On Tuesday, November 6th, David A. Reis sold 11,147 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.64, for a total transaction of $18,281.08.
  • On Friday, November 2nd, David A. Reis sold 19,456 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.64, for a total transaction of $31,907.84.
  • On Monday, October 29th, David A. Reis sold 7,415 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.64, for a total transaction of $12,160.60.
  • On Wednesday, October 10th, David A. Reis sold 3,502 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.63, for a total transaction of $5,708.26.
  • On Tuesday, September 4th, David A. Reis sold 47,755 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.74, for a total transaction of $83,093.70.
  • On Thursday, August 30th, David A. Reis sold 44,975 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.74, for a total transaction of $78,256.50.
  • On Tuesday, August 28th, David A. Reis sold 64,064 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.72, for a total transaction of $110,190.08.
  • On Friday, August 24th, David A. Reis sold 71,070 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.70, for a total transaction of $120,819.00.
  • On Tuesday, August 14th, David A. Reis sold 47,365 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.65, for a total transaction of $78,152.25.

Shares of GEN stock traded down $0.05 on Friday, reaching $1.64. The company had a trading volume of 304,150 shares, compared to its average volume of 207,019. The stock has a market cap of $266.53 million, a PE ratio of -0.78 and a beta of 0.50. Genesis Healthcare Inc has a 12 month low of $0.60 and a 12 month high of $2.86.

Genesis Healthcare (NYSE:GEN) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.25). The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the business posted ($0.34) earnings per share. Analysts anticipate that Genesis Healthcare Inc will post -1.42 EPS for the current year.

Several hedge funds have recently made changes to their positions in GEN. Schwab Charles Investment Management Inc. bought a new stake in shares of Genesis Healthcare in the 1st quarter valued at about $153,000. BlackRock Inc. increased its stake in shares of Genesis Healthcare by 5.8% in the 1st quarter. BlackRock Inc. now owns 2,302,417 shares of the company’s stock valued at $3,476,000 after acquiring an additional 127,118 shares during the last quarter. California Public Employees Retirement System increased its stake in Genesis Healthcare by 23.3% during the 1st quarter. California Public Employees Retirement System now owns 309,910 shares of the company’s stock worth $468,000 after purchasing an additional 58,610 shares in the last quarter. Millennium Management LLC increased its stake in Genesis Healthcare by 40.6% during the 1st quarter. Millennium Management LLC now owns 338,678 shares of the company’s stock worth $511,000 after purchasing an additional 97,834 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Genesis Healthcare by 715.9% during the 2nd quarter. Acadian Asset Management LLC now owns 813,222 shares of the company’s stock worth $1,862,000 after purchasing an additional 713,545 shares in the last quarter. 19.72% of the stock is owned by institutional investors.

GEN has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $7.00 price target on shares of Genesis Healthcare in a research note on Tuesday, August 7th. Credit Suisse Group initiated coverage on Genesis Healthcare in a research note on Tuesday, October 16th. They issued a “neutral” rating and a $1.75 price target for the company. Finally, ValuEngine cut Genesis Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, July 18th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Genesis Healthcare has a consensus rating of “Hold” and an average price target of $3.19.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/11/09/david-a-reis-sells-55020-shares-of-genesis-healthcare-inc-gen-stock.html.

Genesis Healthcare Company Profile

Genesis Healthcare, Inc, together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy.

Read More: 52-Week High/Low

Insider Buying and Selling by Quarter for Genesis Healthcare (NYSE:GEN)

Receive News & Ratings for Genesis Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply